



**Karolinska  
Institutet**

# Carriers of *CYP21A2* mutations have a decreased mortality in infectious diseases: A national population registry study

Anna Nordenström<sup>1,3</sup>, Johan Svensson<sup>1,3</sup>, Svetlana Lajic<sup>1,3</sup>, Louise Frisén, Agneta Nordenskjöld<sup>1</sup>, Christina Norrby<sup>2</sup>, Catarina Almqvist Malmros<sup>2</sup>, Henrik Falhammar<sup>4</sup> <sup>1</sup>Dept of Women's and Children's Health, <sup>2</sup>Dept of Medical Epidemiology and Biostatistics Karolinska Institutet <sup>3</sup>Pediatric Endocrinology, <sup>4</sup>Endocrinology, Metabolism and Diabetes Stockholm, Sweden.

## Conclusions

- *CYP21A2* carriers have a lower mortality in infectious diseases
- Pneumonia as the cause of death was uncommon
- A higher and more prompt cortisol response could be the explanation for an evolutionary advantage of being a carrier of a *CYP21A2*

## Background

Congenital adrenal hyperplasia (CAH) is a relatively common monogenic recessive disorder with an incidence of 1/15 000 in most populations. It has been suggested that *CYP21A2* deficiency is relatively common because it may confer a survival advantage being a carrier. Carriers of *CYP21A2* mutations typically do not have clinical symptoms but have a defined phenotype.

The cortisol response to ACTH stimulation in *CYP21A2* carriers has been shown to be both more prompt and increased compared to healthy, non-carrier, controls.

The carrier frequency the Swedish population is about 1:50 individuals for a mutation in the *CYP21A2* gene and 1:70 for a classic *CYP21A2* mutation.

The over all mortality is lower for women than men.

We investigated the mortality, and cause of mortality in carriers compared to population controls, for men and women.

## Methods

A total of 1143 (561 men, 582 women) obligate carriers of a *CYP21A2* mutation, were identified as parents of patients with known CAH. We used the Swedish National CAH Registry encompassing more than 700 CAH patients and the Multigeneration Registry. Controls were identified from the general population, 100 controls per *CYP21A2* carrier. The mortality and cause of death was identified through the Swedish Cause of Death Registry.

The Hazard Ratio (HR) confidence intervals and p values were calculated.

Study population						
Carriers	Men		Women		Ctrl Men	Ctrl Women
SW	276	136	140		13583	13991
SV	455	223	232		22293	23198
other	412	202	210		20180	20989
total	1143	561	582		56056	58178
SW+SV	731	359	372		35876	37189

  

Mortality								
	Men			Women			All	
	n	Dead	%	n	Dead	%	n	Dead
All, carrier	561	106	18.89	582	65	11.17	1143	171
ctrl	56056	11137	19.87	58178	7362	12.65	114234	18499

Infections	Total carriers	Carriers dead	%	Total controls	Controls dead	%	Hazard Ratio	P
Infections	1143	45	3.94	114234	5640	4.94	<b>0.65 (0.49-0.87)</b>	<b>0.004</b>
sepsis		4	0.35		362	0.32	1.03 (0.38-2.77)	0.952
erysipelas		0			13	0.01		0.993
virus hepatitis		0			51	0.04		0.989
influenza		0			23	0.02		0.993
pneumonia		2	0.17		725	0.63	<b>0.22 (0.06-0.88)</b>	<b>0.032</b>

## Results

The overall mortality was significantly lower in carriers of one of the classic *CYP21A2* mutations compared to the general population, for women (p=0.05), but not for the whole cohort (p=0.13).

Infection as the cause of death was significantly lower in the whole cohort with Hazard Ratio 0.65 (CI 95%, 0.49-0.87; p=0.004).

In particular, a lower mortality in pneumonia was seen HR 0.22 (CI 95%, 0.06-0.88; p=0.03). There was no difference in mortality due to cancer.

The lower overall mortality among women compared to men was confirmed, both among the carriers and the controls (p=0.0001).

## Discussion

Obligate *CYP21A2* carriers (parents of CAH patients) had a reduced mortality, and specifically a reduced mortality due to pneumonia. Our results suggest a better ability to cope with the somatic stress of severe infections among heterozygous carriers of severe *CYP21A2* mutations.

The timing, the prompt and exaggerated increase in cortisol in acute situations, could enable inhibition of the cytokines and other inflammatory factors that induce glucocorticoid resistance, resulting in an evolutionary advantage.

This may contribute to the apparent survival advantage since infectious diseases represent a large cause of death, through evolution.

